Pathogenesis of CCR5-restricted HIV-1
Pathogenesis of CCR5-restricted HIV-1
批准号:
nhmrc : 433915
负责人:
Dr Pantelis Poumbourios
金额:
$25.12万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2007
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2007-01-01 至 2009-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Human immunodeficiency virus type 1 (HIV-1) causes AIDS and, to date, has infected approximately 20 thousand people in Australia and more than 40 million worldwide. People infected with HIV-1 first experience a period of 5-7 years where they remain healthy, ofter assisted by the use of anti-HIV-1 drugs, and this period is referred to as the asymptomatic period. After this period, infected individuals become sick due to their immune system being destroyed, and this is referred to as AIDS. Research into how HIV-1 causes AIDS has shown us that the virus changes over time to make itself better able to kill cells of the immune system, by at least 2 mechanisms. The first mechanism, which is the best characterised one, is where the virus changes the way it infects cells, whereby it can infect many more cells in the body by taking advantage of an alternate receptor molecule on the cell called CXCR4. This molecule is very widely expressed on immune cells, and thus the virus can now infect and kill many more cells. However, in about 50% of infected people who eventually get AIDS, the virus does not change this way. The virus instead uses it's original receptor to infect cells, called CCR5. Our preliminary studies, as well as other published reports, suggest that the virus changes itself another way to make it kill immune cells better, without using CXCR4. However, the mechanism by which HIV-1 does this is poorly understood. This proposal aims to better understand this mechanism. We expect to find that, in this group of patients, the Env proteins on the virus change to be able to bind CCR5 more tightly, and thus be able to use fewer molecules of CCR5 to infect cells. We believe that these forms of the virus are now better able to kill immune cells, leading to AIDS. This study will contribute to a greater understanding of how HIV-1 causes AIDS, which is necessary for the development of new drugs to treat HIV-1 infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structural basis of HIV and HTLV entry
-
批准号:nhmrc : 991153
-
项目类别:NHMRC Strategic Awards
-
资助金额:$41.38万
-
财政年份:1999
-
负责人:Dr Pantelis Poumbourios
-
依托单位:
Structure of chemokine receptor gp120 complex
-
批准号:nhmrc : 981177
-
项目类别:NHMRC Strategic Awards
-
资助金额:$15.3万
-
财政年份:1998
-
负责人:Dr Pantelis Poumbourios
-
依托单位:
Antiviral agents that disrupt the HIV envelope protein function
-
批准号:nhmrc : 956047
-
项目类别:CARG - Research
-
资助金额:$5.91万
-
财政年份:1995
-
负责人:Dr Pantelis Poumbourios
-
依托单位:
国内基金
海外基金
登录
查看更多内容
IL-17/CCL3/CCR5介导星形胶质细胞与小胶质细胞相互作用在心脏骤停致 神经炎症反应中的作用机制研究
-
批准号:2026JJ50568
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:邹联洪
-
依托单位:
趋化因子受体5(CCR5)相关信号通路对缺血性脑卒中的调节机制及L-茶氨酸的干预作用研究
-
批准号:2025JJ90021
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:黄晓松
-
依托单位:
胆汁酸—趋化因子受体CCR5轴促进胆道
闭锁的机制研究及靶向策略建立
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:罗镇华
-
依托单位:
基于“ 肾-骨髓-脑 ”轴探讨左归丸通过调控
CCL5/CCR5 轴对多发性硬化的作用机制研究
-
批准号:TGY24H270026
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:陈克龙
-
依托单位:
CCL5/CCR5轴趋化小胶质细胞活化经PAK1-Cofilin通路致神经突触可塑性改变在SPISD中的作用及机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:代月娥
-
依托单位:
CCL5 –CCR5 信号通路调控小胶质细胞活化在网状
脊髓束过度兴奋中的机制及白芍络石方干预作用
-
批准号:2024JJ5235
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:谢乐
-
依托单位:
巨噬细胞Piezo1调控背根神经节CCR5在骨癌痛中的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:杭黎华
-
依托单位:
基于近程标记和蛋白质谱检测解析CCR5调控TGFβ1表达及黑色素瘤转移的机制
-
批准号:32301234
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘洁
-
依托单位:
五羟色胺受体5-HT7R通过CCR5调控免疫稳态、促进感染恢复的机制研究
-
批准号:82371776
-
项目类别:面上项目
-
资助金额:50万元
-
批准年份:2023
-
负责人:韩根成
-
依托单位:
龙血竭活性成分抑制CKLF1/CCR5诱导的NETs促进脑卒中后血运重塑及功能修复
-
批准号:82374060
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张钊
-
依托单位: